» Articles » PMID: 34264565

Antimicrobial Treatment and Prophylaxis of Plague: Recommendations for Naturally Acquired Infections and Bioterrorism Response

Overview
Journal MMWR Recomm Rep
Specialty Public Health
Date 2021 Jul 15
PMID 34264565
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

This report provides CDC recommendations to U.S. health care providers regarding treatment, pre-exposure prophylaxis, and postexposure prophylaxis of plague. Yersinia pestis, the bacterium that causes plague, leads to naturally occurring disease in the United States and other regions worldwide and is recognized as a potential bioterrorism weapon. A bioweapon attack with Y. pestis could potentially infect thousands, requiring rapid and informed decision making by clinicians and public health agencies. The U.S. government stockpiles a variety of medical countermeasures to mitigate the effects of a bioterrorism attack (e.g., antimicrobials, antitoxins, and vaccines) for which the 21st Century Cures Act mandates the development of evidence-based guidelines on appropriate use. Guidelines for treatment and postexposure prophylaxis of plague were published in 2000 by a nongovernmental work group; since then, new human clinical data, animal study data, and U.S. Food and Drug Administration approvals of additional countermeasures have become available. To develop a comprehensive set of updated guidelines, CDC conducted a series of systematic literature reviews on human treatment of plague and other relevant topics to collect a broad evidence base for the recommendations in this report. Evidence from CDC reviews and additional sources were presented to subject matter experts during a series of forums. CDC considered individual expert input while developing these guidelines, which provide recommended best practices for treatment and prophylaxis of human plague for both naturally occurring disease and following a bioterrorism attack. The guidelines do not include information on diagnostic testing, triage decisions, or logistics involved in dispensing medical countermeasures. Clinicians and public health officials can use these guidelines to prepare their organizations, hospitals, and communities to respond to a plague mass-casualty event and as a guide for treating patients affected by plague.

Citing Articles

Assessing the threat of harboring a multi-resistant IncC plasmid and the efficacy of an antibiotic targeting LpxC.

Lemaitre N, Dewitte A, Rakotomanimana F, Gooden D, Toone E, Rajerison M Antimicrob Agents Chemother. 2025; 69(3):e0149724.

PMID: 39882860 PMC: 11881579. DOI: 10.1128/aac.01497-24.


Development of Effective Medical Countermeasures Against the Main Biowarfare Agents: The Importance of Antibodies.

Avril A, Guillier S, Rasetti-Escargueil C Microorganisms. 2025; 12(12.

PMID: 39770824 PMC: 11677989. DOI: 10.3390/microorganisms12122622.


Vector-Borne Zoonotic Lymphadenitis-The Causative Agents, Epidemiology, Diagnostic Approach, and Therapeutic Possibilities-An Overview.

Orsolic M, Sarac N, Topic M Life (Basel). 2024; 14(9).

PMID: 39337966 PMC: 11433605. DOI: 10.3390/life14091183.


Exploring and Mitigating Plague for One Health Purposes.

Eads D, Biggins D, Wimsatt J, Eisen R, Hinnebusch B, Matchett M Curr Trop Med Rep. 2024; 9(4):169-184.

PMID: 39210935 PMC: 11358858. DOI: 10.1007/s40475-022-00265-6.


Sex differences in immune protection in mice conferred by heterologous vaccines for pneumonic plague.

Davies M, Biryukov S, Rill N, Klimko C, Hunter M, Dankmeyer J Front Immunol. 2024; 15:1397579.

PMID: 38835755 PMC: 11148226. DOI: 10.3389/fimmu.2024.1397579.


References
1.
Luo H, Dong X, Li F, Xie X, Song Z, Shao Z . A cluster of primary pneumonic plague transmitted in a truck cab in a new enzootic focus in China. Am J Trop Med Hyg. 2013; 88(5):923-8. PMC: 3752759. DOI: 10.4269/ajtmh.12-0163. View

2.
LANDSBOROUGH D, TUNNELL N . Observations on plague meningitis. Br Med J. 2010; 1(4487):4-7. PMC: 2052269. DOI: 10.1136/bmj.1.4487.4. View

3.
. Imported plague--New York City, 2002. MMWR Morb Mortal Wkly Rep. 2003; 52(31):725-8. View

4.
Hull H, Montes J, Mann J . Septicemic plague in New Mexico. J Infect Dis. 1987; 155(1):113-8. DOI: 10.1093/infdis/155.1.113. View

5.
Galimand M, Carniel E, Courvalin P . Resistance of Yersinia pestis to antimicrobial agents. Antimicrob Agents Chemother. 2006; 50(10):3233-6. PMC: 1610074. DOI: 10.1128/AAC.00306-06. View